Acalabrutinib

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 736 publications

An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis.

An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis.

Journal: Leukemia & lymphoma

Published: June 21, 2026

The preclinical discovery and development of acalabrutinib for the treatment of mantle cell lymphoma.

The preclinical discovery and development of acalabrutinib for the treatment of mantle cell lymphoma.

Journal: Expert opinion on drug discovery

Published: June 15, 2026

All-oral combination of acalabrutinib plus venetoclax approved for adults with CLL or SLL: Phase 3 AMPLIFY trial results show significantly improved progression-free survival in comparison with standard chemoimmunotherapy.

All-oral combination of acalabrutinib plus venetoclax approved for adults with CLL or SLL: Phase 3 AMPLIFY trial results show significantly improved progression-free survival in comparison with standard chemoimmunotherapy.

Journal: Cancer

Published: June 02, 2026

From covalent to reversible: the expanding role of BTK inhibitors in chronic lymphocytic leukemia.

From covalent to reversible: the expanding role of BTK inhibitors in chronic lymphocytic leukemia.

Journal: Expert opinion on pharmacotherapy

Published: May 29, 2026

Clinical Safety Profile of Bruton's Tyrosine Kinase (BTK) Inhibitors in Chronic Lymphocytic Leukaemia: A Real-World Ambispective Study From India.

Clinical Safety Profile of Bruton's Tyrosine Kinase (BTK) Inhibitors in Chronic Lymphocytic Leukaemia: A Real-World Ambispective Study From India.

Journal: Cureus

Published: May 19, 2026

More than an attachment module: covalent inhibitor warheads influence BTK dynamics and function.

More than an attachment module: covalent inhibitor warheads influence BTK dynamics and function.

Journal: bioRxiv : the preprint server for biology

Published: May 18, 2026

Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL.

Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL.

Journal: Oncology and therapy

Published: April 21, 2026

Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B-cell malignancies: A nationwide population-based study.

Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B-cell malignancies: A nationwide population-based study.

Journal: British journal of haematology

Published: April 20, 2026

From Solid Organ Malignancies to Dual Leukaemias: Sequential CLL and CML in a Cancer Survivor.

From Solid Organ Malignancies to Dual Leukaemias: Sequential CLL and CML in a Cancer Survivor.

Journal: European journal of case reports in internal medicine

Published: April 20, 2026

The Immunologic Paradox of BTK Inhibitors in Chronic Lymphocytic Leukemia: Selectivity, Hypogammaglobulinemia, and Infection Risk.

The Immunologic Paradox of BTK Inhibitors in Chronic Lymphocytic Leukemia: Selectivity, Hypogammaglobulinemia, and Infection Risk.

Journal: Cancers

Published: April 19, 2026

CLO26-111: Treatment-Naïve CLL in Routine Care: Acalabrutinib Monotherapy Versus Acalabrutinib Plus Obinutuzumab.

CLO26-111: Treatment-Naïve CLL in Routine Care: Acalabrutinib Monotherapy Versus Acalabrutinib Plus Obinutuzumab.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN

Published: April 16, 2026

Effect of age and sex on cardiovascular outcomes among patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors: a propensity matched analysis.

Effect of age and sex on cardiovascular outcomes among patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors: a propensity matched analysis.

Journal: Leukemia & lymphoma

Published: April 11, 2026

Showing 1-12 of 736

Last Updated: 06/30/2026